Inhibikase Therapeutics (IKT) Interest Expenses (2020 - 2025)
Inhibikase Therapeutics (IKT) posted quarterly Interest Expenses of $31.7 million for Q4 2025, up 82512.71% quarter-over-quarter from $38322.0 in Q2 2025.
Inhibikase Therapeutics (IKT) Interest Expenses (2020 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Interest Expenses for 6 consecutive years, with $31.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses changed N/A year-over-year to $31.7 million; the TTM figure through Dec 2025 stood at $31.7 million (changed N/A YoY), while the FY2025 annual figure was $31.7 million, up 1.8% from the prior year.
- Interest Expenses advanced to $31.7 million in Q4 2025 per IKT's latest filing, from $38322.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $31.7 million in Q4 2025 and bottomed at -$18460.0 in Q4 2021.
- Historically, Interest Expenses has averaged $2.2 million across 5 years, with a median of $32275.0 in 2023.
- Annual changes were most pronounced in 2021 — Interest Expenses sank 358.58% — and 2022, when it soared 44675.8%.
- Inhibikase Therapeutics' Interest Expenses stood at -$18460.0 in 2021, then surged by 480.81% to $70298.0 in 2022, then slumped by 54.09% to $32275.0 in 2023, then soared by 374.94% to $153288.0 in 2024, then soared by 20553.18% to $31.7 million in 2025.
- Business Quant data shows IKT's Interest Expenses at $31.7 million in Q4 2025, $38322.0 in Q2 2025, and $1872.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 31.66 Mn |
| Dec 31, 2025 | 31.66 Mn |
| Jun 30, 2025 | 38,322.00 |
| Jun 30, 2025 | 38,322.00 |
| Mar 31, 2025 | 1,872.00 |
| Mar 31, 2025 | 1,872.00 |
| Sep 30, 2024 | 153,288.00 |
| Sep 30, 2024 | 153,288.00 |
| Jun 30, 2024 | 190,546.00 |
| Jun 30, 2024 | 190,546.00 |
| Mar 31, 2024 | 18,314.00 |
| Mar 31, 2024 | 18,314.00 |
| Sep 30, 2023 | 32,275.00 |
| Sep 30, 2023 | 32,275.00 |
| Jun 30, 2023 | 40,574.00 |
| Jun 30, 2023 | 40,574.00 |
| Mar 31, 2023 | 49,693.00 |
| Mar 31, 2023 | 49,693.00 |
| Sep 30, 2022 | 70,298.00 |
| Sep 30, 2022 | 70,298.00 |